Compare iShares Bitcoin Trust (IBIT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Repligen Corporation Common Stock — how do they compare? iShares Bitcoin Trust trades at $45.76 (market cap $66.80B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: iShares Bitcoin Trust is far larger — about 5.9× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 42 Days and Repligen Corporation Common Stock for 0 Days on average.
| IBIT | RGEN | |
|---|---|---|
Market Cap | $66.80B | $11.31B |
Volume | 40,279,711 | 1,216,919 |
Sector | Crypto-linked | Health |
52-Week High | $65.28 | $194.57 |
52-Week Low | $33.29 | $102.87 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.13, up 0.58% with neutral technical signals. The stock shows bullish moving average momentum but faces resistance at $48. Recent inflows of $196 million on October 1, 2026, highlight renewed institutional interest in BlackRock's ETF offerings, though financial ratios remain undisclosed.
Outlook remains balanced with technical support at $46-$47. Key risks include market volatility and regulatory uncertainty. Analyst sentiment is mixed, with institutional flows suggesting cautious optimism amid broader crypto ETF market resilience.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
